Sarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at Barclays

Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Barclays from $22.00 to $20.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on the company. Bank of America increased their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a report on Wednesday, October 22nd. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $19.00 to $26.00 in a report on Wednesday. Morgan Stanley increased their price objective on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, July 29th. Finally, Leerink Partners increased their price objective on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a report on Tuesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $33.75.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $18.67 on Wednesday. The stock has a 50 day moving average price of $20.33 and a 200 day moving average price of $26.23. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -21.46 and a beta of 0.52. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. Sarepta Therapeutics’s revenue was down 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 earnings per share. Research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Pandora Wealth Inc. purchased a new position in Sarepta Therapeutics in the first quarter worth $45,000. Brooklyn Investment Group raised its position in Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 590 shares in the last quarter. Banque Transatlantique SA purchased a new position in Sarepta Therapeutics in the first quarter worth $44,000. Finally, Hurley Capital LLC raised its position in Sarepta Therapeutics by 139.2% in the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 835 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.